Project title: TOPICAL DERMATOLOGICAL PRODUCTS

Company name : MEDIDERMIS

TECHNOLOGICAL FIELD
Biotechnology

KEY WORDS
Acne Vulgaris, Topical
Cream, Acne, Dermatology

PROJECT SUMMARY
Acne is a field without a topical market leader. The Medidermis
innovative niche product is intended to close a gap between the
relative lack of efficacy of existing topical treatments
(Adalpalene, Galderma) and the high cost, high side effect but
efficient oral Isotretinoin (Accutane, Roche). The product is
targeted to become the market leader in the field of Acne.
Although recently introduced, the topical anti-acne cream has
reached a successful proof of concept stage. It was proven that
the product achieves results comparable with those of Accutane,
but features a competitive advantages of being a topical cream
and achieving faster results without the Accutane side effects.
The drug (not a new molecule) is highly active against
inflammatory lesions, from papules to pustules and white comedos
as well. It is the only known product able to dissolute white
comedos within 30 days.

MARKETS
Acne Vulgaris is a ubiquitous disease effecting about 85% of the
population with an equal distribution between sexes, at any stage
of their lives from 12-25 years old. It is caused by genetic and
environmental triggers, as shown by 1% disease prevalence in
isolated exotic (Papua) populations. About 2-4% of the subjects
that suffer from acne are beyond 25 years old.
The disease bears a remarkable economical impact since in the US
only over 6.5 million patients each year visit physicians for
acne treatment. The U.S. market for prescription acne medications
was approximately US$1.6 billion in 2002 and is forecast to
increase to US$1.9 billion by 2006. The global market for
prescription anti-acne products reached US$2.0 billion in 2001
and is forecast to reach US$3.3 billion in 2006.

ENTREPRENEUR
Dr. Avi Dascalu - General Manager,
M.D., Ph.D., Dermatologist, Advisor of Physiology and
Pharmacology department, Sackler School of Medicine, Tel Aviv
University.

PROJECT STATUS
The Project completed incubator period. The company is facing a
strategic investment.

COOPERATION REQUIRED
Seeking strategic partnerships and funding.
---------------------------------------------------------------
TEL: 972-9-8357302 FAX: 972-9-8851090 E-MAIL: dasc@post.tau.ac.il

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about